Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
Wolfgang Wick(German Cancer Research Center), Martin J. van den Bent(Erasmus MC Cancer Institute), Jacoline E. C. Bromberg(Erasmus MC), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Julien Dômont(Heidelberg University), Roger Stupp(Northwestern University), Felix Sahm(German Cancer Research Center), Michael Platten(German Cancer Research Center), Davide Musmeci(European Organisation for Research and Treatment of Cancer), Émilie Le Rhun(University of Zurich), Maaike J. Vos(Medisch Centrum Haaglanden), Michel Fabbro(Nordic Society of Gynecologic Oncology), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Vassilis Golfinopoulos(Champalimaud Foundation), Paul M. Clément(Universitair Ziekenhuis Leuven), François Dubois(Hôpital Roger Salengro), Martin Bendszus(Heidelberg University)
Cited by 19
Related Papers
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k